Epilepsy

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 11, 2020.

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.

Treating patients with super-refractory status epilepticus with ketamine showed no effect on intracranial pressure, cerebral blood flow, and cerebral perfusion pressure.

The neurology resident at NYU Langone described psychosocial implications that physicians faced during the COVID-19 pandemic and the toll it takes on them.

Neurology News Network for the week ending September 5, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 4, 2020.

Multidisciplinary teams who had the pocket card available had shorter times to rescue therapy initiation and similar rates of adequate dosing.

The pediatric neurologist at Hurley Medical Center of the University of Michigan Hospitals-Michigan Medicine, detailed the challenges those with epilepsy face when transitioning to adult care.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed the reasons why epilepsy surgery is not utilized as often as it should, and her efforts to raise awareness.

The FDA-approved epilepsy monotherapy showed significant reductions in primary generalized tonic-clonic seizures of ≥50% and ≥75% from baseline.

A low glycemic index therapy diet is associated with the least number of and least severe adverse events among all 3 epileptic diet methods, with similar reductions in seizure burden.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed how recent study findings might impact the patient perspective on epilepsy surgery.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.

Could expanding insights into the pathophysiology of autoimmune epilepsy offer seizure-free hope for patients?

The first-in-class CH24H inhibitor was associated with a reduction in seizures and seizure frequency in an early analysis of the phase 2 ELEKTRA study, with plans to initiate the move to phase 3 in Dravet syndrome.

The investgators noted that the absences before the tonic-clonic convulsions can be as short as 5 seconds, suggesting they may be more frequently occurring than those being observed or reported.

Neurology News Network for the week ending August 22, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed the patient-centered pros and cons associated with epilepsy surgery, as well as the stigmas related to it.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed her most recent findings on the cost-effectiveness of epilepsy surgery for drug-resistant temporal lobe epilepsy.

The goal is to improve the delivery of care and outcomes for patients with epilepsy as they transition from pediatric to adult care settings, where there is often less oversight.

Patients with refractory temporal lobe epilepsy may be more inclined to opt for surgery when they understand the long-term cost effectiveness, as well as rates of increased seizure freedom and reduced seizure relapses.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

Future studies may validate the use of routine electroencephalogram as an alternative to continuous electroencephalogram in centers with limited resources, as despite better seizure detection with continuous monitoring, outcomes were similar between the methods.

Neurology News Network for the week ending August 8, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.

Marinus Pharmaceuticals, the agent’s manufacturer, plans to announce topline data from the phase 3 Marigold study in the third quarter of this year.

An overview of the tweet chat on mental health in neurological disorders, featuring highlighted contributions from the medical community.

The approval also expands the age range of all Epidiolex indications to include patients age 1 and older.

NeuroPace’s FDA-approved neurostimulation device helped 35% of patients with epilepsy achieve ≥90% reduction in seizure frequency, with 18% of patients reporting seizure freedom at last follow-up.